slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 87,961-87,990
Pages 3,225
Rows per page 30
Component
87,961-87,990 of 96,741
06
Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slidesAeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank Beat · Problem & Complication1 hit
21
The chart uses a regression line to correlate human and NHP half-lives, highlighting the 3.1x multiplier for YTE-modified antibodies.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
23
The chart combines a bar chart of competitor benchmarks with a bar chart showing vedolizumab's exposure-response quartiles.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
28
The chart compares clinical remission rates across different drug classes (TL1A, a4b7, IL-23s, TNFas, S1P1s, JAKs) with a safety gradient indicated on the Y-axis.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
31
The slide uses a bar chart to compare efficacy and provides a strategic rationale for pursuing both monomeric/trimeric and trimeric-only approaches.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
32
Includes two charts: a dose-response curve and a scatter plot of potency vs. binding specificity.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
33
The table contrasts established drugs (with confirmed exposure-response) against newer anti-TL1A agents (PRA023, RVT-3101) where this relationship is currently TBD.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
37
The slide uses a biological process diagram to illustrate drug targets (a4b7, TL1A, IL-23) and their corresponding therapeutic antibodies.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
38
The slide uses a bar chart to illustrate additive clinical remission rates, with a table below providing additional clinical metrics (N, maintenance remission, safety).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
40
Includes a specific note that this is an 'Illustrative example' and 'Preliminary; pending regulatory feedback'.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
43
The slide uses a comparative bar chart structure to show the delta in efficacy when using a companion diagnostic (CDx).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
46
The slide uses a table-based timeline format to track R&D progress and external data readouts.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
47
The table uses a custom visualization for market cap range (min, IPO, today, max) and clinical stage progression.Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
48
The table maps historical industry M&A deals to Spyre's internal pipeline development milestones (2025-2027).Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · Aeglea BioTherapeutics
Deck Investment bank 1 hit
04
Alkermes | Investor Presentation Deck | 56 slidesAlkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Current Reality (Pain)1 hit
08
The slide uses a three-column layout to present strategic priorities, with a footer highlighting stock performance relative to peers.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Future Vision (Gain)1 hit
13
The slide highlights a 50% improvement in valuation multiple despite a decline in the NBI index multiple.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
16
The slide uses a dual-axis timeline (top and bottom) to annotate events on a stock price chart.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & Proof1 hit
17
The table categorizes products into 'Proprietary' and 'Royalty' streams.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Mece Breakdown1 hit
19
The slide uses a bar chart to show quarterly net sales growth from Q4'21 to Q1'23.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Mece Breakdown1 hit
20
The slide uses donut charts to represent revenue composition and growth.Alkermes | Investor Presentation Deck | 56 slides · Alkermes
Conference presentation Investor relations Beat · Evidence & ProofLoop · Mece Breakdown1 hit
20
The slide uses a visual metaphor of a smart speaker to illustrate the concept of 'anywhere' access to information.Taboola | Investor Presentation Deck | 64 slides · Taboola
Pitch deck Investor relations Beat · Satisfaction1 hit
41
Includes CAGR calculation and YoY growth metrics.Taboola | Investor Presentation Deck | 64 slides · Taboola
Pitch deck Investor relations 1 hit
16
Includes company branding and study logo.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
35
The slide uses a mathematical formula structure to explain revenue recognition.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
38
Uses a funnel diagram to illustrate market penetration.Theravance Biopharma | Results Presentation Deck | 41 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Before-After1 hit
16
The slide explains the dual-class structure and how it relates to financial reporting and economic interest.Vivid Seats | Results Presentation Deck | 20 slides · Vivid Seats
Conference presentation Investor relations 1 hit
08
Includes revenue from DR.WU (mainland China), Galénic, Eve Lom, Abby's Choice, and others.Yatsen | Results Presentation Deck | 16 slides · Yatsen Holding Limited
Conference presentation Investor relations Loop · So What Cascade1 hit
09
The slide highlights a 59% YoY growth in combined net revenues for the three brands.Yatsen | Results Presentation Deck | 16 slides · Yatsen Holding Limited
Conference presentation Investor relations Loop · So What Cascade1 hit
10
The chart highlights a strategic reduction in offline retail footprint throughout 2022.Yatsen | Results Presentation Deck | 16 slides · Yatsen Holding Limited
Conference presentation Investor relations 1 hit